I agree with this completely. The share price and Daybue results are out of Neuren's hands. We can only hope for the best.
The real driver of long-term value is NNZ-2591. In that respect, the upcoming Angelman results and FDA meeting for Phase III (and revised Phase II) protocol will be key.
If those results are positive, and the company provides an update on the path forward for NNZ-2591, one would have to think the fortunes of the stock could change quickly. That is not to mention the new indications and potential partnering/takeover interest.
Share Price, page-10995
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $18.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.65 | 1127 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |